There are currently 34 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
NCT04739813
Recruiting
Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remissions. Researchers want to see if a combination of drugs can help patients with both aggressive and indolent B-cell lymphomas. Objective: To learn if it is safe and effectiv... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Register for Updates
Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
NCT04512716
Recruiting
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
Register for Updates
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
NCT05256641
Recruiting
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California +2 locations
Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
Register for Updates
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05498220
Recruiting
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back or did not improve after the treatments (rrDLBCL). This combination has not been approved by the Food and Drug Administration (FDA) for the treatment of rrDLBCL. Salvage therapy (treatment after standard treatment failed) needs to be improved. Ritu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
NCT05432635
Recruiting
This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patients with high grade B-cell non-Hodgkin lymphoma. CAR T-cells are a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T-cells are taken from a patient's blood.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Register for Updates
Evaluation of Human Immune Responses Vaccination in Patients with Lymphoma
NCT03501576
Recruiting
This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Register for Updates
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +75 locations
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Register for Updates
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Alabama Oncology, Birmingham, Alabama +24 locations
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: UACC Arizona, Tucson, Arizona +175 locations
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
NCT02393157
Recruiting
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 3 years and 31 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York
Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Register for Updates